The Role of FasL and Fas in Health and Disease

  • Martin Ehrenschwender
  • Harald Wajant
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 647)


The FS7-associated cell surface antigen (Fas, also named CD95, APO-1 or TNFRSF6) attracted considerable interest in the field of apoptosis research since its discovery in 1989. The groups of Shin Yonehara and Peter Krammer were the first reporting extensive apoptotic cell death induction upon treating cells with Fas-specific monoclonal antibodies.1,2 Cloning of Fas3 and its ligand,4,5 FasL (also known as CD178, CD95L or TNFSF6), laid the cornerstone in establishing this receptor-ligand system as a central regulator of apoptosis in mammals. Therapeutic exploitation of FasL-Fas-mediated cytotoxicity was soon an ambitous goal and during the last decade numerous strategies have been developed for its realization. In this chapter, we will briefly introduce essential general aspects of the FasL-Fas system before reviewing its physiological and pathophysiological relevance. Finally, FasL-Fas-related therapeutic tools and concepts will be addressed.


FasL Expression Immune Privilege Soluble FasL Membrane FasL 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen codownregulated with the receptor of tumor necrosis factor. J Exp Med 1989; 169:1747–1756.PubMedCrossRefGoogle Scholar
  2. 2.
    Trauth BC, Klas C, Peters AM et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245:301–305.PubMedCrossRefGoogle Scholar
  3. 3.
    Itoh N, Yonehara S, Ishii A et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66:233–243.PubMedCrossRefGoogle Scholar
  4. 4.
    Suda T, Takahashi T, Golstein P et al. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75:1169–1178.PubMedCrossRefGoogle Scholar
  5. 5.
    Takahashi T, Tanaka M, Inazawa J et al. Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol 1994; 6:1567–1574.PubMedCrossRefGoogle Scholar
  6. 6.
    Cheng J, Liu C, Koopman WJ et al. Characterization of human Fas gene. Exon/intron organization and promoter region. J Immunol 1995; 154:1239–1245.PubMedGoogle Scholar
  7. 7.
    Wajant H, Pfizenmaier K, Scheurich P. Non-apoptotic Fas signaling. Cytokine Growth Factor Rev 2003; 14:53–66.PubMedCrossRefGoogle Scholar
  8. 8.
    Cheng J, Zhou T, Liu C et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263:1759–1762.PubMedCrossRefGoogle Scholar
  9. 9.
    Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001; 104:487–501.PubMedCrossRefGoogle Scholar
  10. 10.
    Zhang G. Tumor necrosis factor family ligand-receptor binding. Curr Opin Struct Biol 2004; 14:154–160.PubMedCrossRefGoogle Scholar
  11. 11.
    Orlinick JR, Vaishnaw A, Elkon KB et al. Requirement of cysteine-rich repeats of the Fas receptor for binding by the Fas ligand. J Biol Chem 1997; 272:28889–28894.PubMedCrossRefGoogle Scholar
  12. 12.
    Starling GC, Bajorath J, Emswiler J et al. Identification of amino acid residues important for ligand binding to Fas. J Exp Med 1997; 185:1487–1492.PubMedCrossRefGoogle Scholar
  13. 13.
    Papoff G, Hausler P, Eramo A et al. Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor. J Biol Chem 1999; 274:38241–38250.PubMedCrossRefGoogle Scholar
  14. 14.
    Siegel RM, Frederiksen JK, Zacharias DA et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 2000; 288:2354–2357.PubMedCrossRefGoogle Scholar
  15. 15.
    Itoh N, Nagata S. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 1993; 268:10932–10937.PubMedGoogle Scholar
  16. 16.
    Chan FK, Chun HJ, Zheng L et al. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000; 288:2351–2354.PubMedCrossRefGoogle Scholar
  17. 17.
    Fesik SW. Insights into programmed cell death through structural biology. Cell 2000; 103:273–282.PubMedCrossRefGoogle Scholar
  18. 18.
    Stahnke K, Hecker S, Kohne E et al. CD95 (APO-1/FAS)-mediated apoptosis in cytokine-activated hematopoietic cells. Exp Hematol 1998; 26:844–850.PubMedGoogle Scholar
  19. 19.
    Orlinick JR, Elkon KB, Chao MV. Separate domains of the human Fas ligand dictate self-association and receptor binding. J Biol Chem 1997; 272:32221–32229.PubMedCrossRefGoogle Scholar
  20. 20.
    Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci 2002; 27:19–26.PubMedCrossRefGoogle Scholar
  21. 21.
    Gruss HJ, Dower SK. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood 1995; 85:3378–3404.PubMedGoogle Scholar
  22. 22.
    Wenzel J, Sanzenbacher R, Ghadimi M et al. Multiple interactions of the cytosolic polyproline region of the CD95 ligand: Hints for the reverse signal transduction capacity of a death factor. FEBS Lett 2001; 509:255–262.PubMedCrossRefGoogle Scholar
  23. 23.
    Blott EJ, Bossi G, Clark R et al. Fas ligand is targeted to secretory lysosomes via a proline-rich domain in its cytoplasmic tail. J Cell Sci 2001; 114:2405–2416.PubMedGoogle Scholar
  24. 24.
    Janssen O, Qian J, Linkermann A et al. CD95 ligand—Death factor and costimulatory molecule? Cell Death Differ 2003; 10:1215–1225.PubMedCrossRefGoogle Scholar
  25. 25.
    Wetzel M, Li L, Harms KM et al. Tissue inhibitor of metalloproteinases-3 facilitates Fas-mediated neuronal cell death following mild ischemia. Cell Death Differ 2007; 15:143–151.PubMedCrossRefGoogle Scholar
  26. 26.
    Kayagaki N, Kawasaki A, Ebata T et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995; 182:1777–1783.PubMedCrossRefGoogle Scholar
  27. 27.
    Mitsiades N, Yu WH, Poulaki V et al. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 2001; 61:577–581.PubMedGoogle Scholar
  28. 28.
    Tanaka M, Itai T, Adachi M et al. Downregulation of Fas ligand by shedding. Nat Med 1998; 4:31–36.PubMedCrossRefGoogle Scholar
  29. 29.
    Schneider P, Holler N, Bodmer JL et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998; 187:1205–1213.PubMedCrossRefGoogle Scholar
  30. 30.
    Shudo K, Kinoshita K, Imamura R et al. The membrane-bound but not the soluble form of human Fas ligand is responsible for its inflammatory activity. Eur J Immunol 2001; 31:2504–2511.PubMedCrossRefGoogle Scholar
  31. 31.
    Aoki K, Kurooka M, Chen JJ et al. Extracellular matrix interacts with soluble CD95L: Retention and enhancement of cytotoxicity. Nat Immunol 2001; 2:333–337.PubMedCrossRefGoogle Scholar
  32. 32.
    Ottonello L, Tortolina G, Amelotti M et al. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. J Immunol 1999; 162:3601–3606.PubMedGoogle Scholar
  33. 33.
    Seino K, Iwabuchi K, Kayagaki N et al. Chemotactic activity of soluble Fas ligand against phagocytes. J Immunol 1998; 161:4484–4488.PubMedGoogle Scholar
  34. 34.
    Lee KH, Feig C, Tchikov V et al. The role of receptor internalization in CD95 signaling. EMBO J 2006; 25:1009–1023.PubMedCrossRefGoogle Scholar
  35. 35.
    Algeciras-Schimnich A, Shen L, Barnhart BC et al. Molecular ordering of the initial signaling events of CD95. Mol Cell Biol 2002; 22:207–220.PubMedCrossRefGoogle Scholar
  36. 36.
    Legembre P, Daburon S, Moreau P et al. Cutting Edge: modulation of Fas-mediated apoptosis by lipid rafts in T lymphocytes. J Immunol 2006; 176:716–720.PubMedGoogle Scholar
  37. 37.
    Eramo A, Sargiacomo M, Ricci-Vitiani L et al. CD95 death inducing signaling complex formation and internalization occur in lipid rafts of type I and type II cells. Eur J Immunol 2004; 34:1930–1940.PubMedCrossRefGoogle Scholar
  38. 38.
    Henkler F, Behrle E, Dennehy KM et al. The extracellular domains of FasL and Fas are sufficient for the formation of supramolecular FasL-Fas clusters of high stability. J Cell Biol 2005; 168:1087–1098.PubMedCrossRefGoogle Scholar
  39. 39.
    Siegel RM, Muppidi JR, Sarker M et al. SPOTS: signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane. J Cell Biol 2004; 167:735–744.PubMedCrossRefGoogle Scholar
  40. 40.
    Muzio M, Chinnaiyan AM, Kischkel FC et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996; 85:817–827.PubMedCrossRefGoogle Scholar
  41. 41.
    Chinnaiyan AM, O’Rourke K, Tewari M et al. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81:505–512.PubMedCrossRefGoogle Scholar
  42. 42.
    Boldin MP, Varfolomeev EE, Pancer Z et al. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 1995; 270:7795–7798.PubMedCrossRefGoogle Scholar
  43. 43.
    Donepudi M, Mac SA, Briand C et al. Insights into the regulatory mechanism for caspase-8 activation. Mol Cell 2003; 11:543–549.PubMedCrossRefGoogle Scholar
  44. 44.
    Boatright KM, Renatus M, Scott FL et al. A unified model for apical caspase activation. Mol Cell 2003; 11:529–541.PubMedCrossRefGoogle Scholar
  45. 45.
    Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003; 10:26–35.PubMedCrossRefGoogle Scholar
  46. 46.
    Barnhart BC, Alappat EC, Peter ME. The CD95 type I/type II model. Semin Immunol 2003; 15:185–193.PubMedCrossRefGoogle Scholar
  47. 47.
    Vaux DL, Silke J. Mammalian mitochondrial IAP binding proteins. Biochem Biophys Res Commun 2003; 304:499–504.PubMedCrossRefGoogle Scholar
  48. 48.
    Vande WL, Lamkanfi M, Vandenabeele P. The mitochondrial serine protease HtrA2/Omi: An overview. Cell Death Differ 2008Google Scholar
  49. 49.
    Riedl SJ, Salvesen GS. The apoptosome: Signalling platform of cell death. Nat Rev Mol Cell Biol 2007; 8:405–413.PubMedCrossRefGoogle Scholar
  50. 50.
    Holler N, Zaru R, Micheau O et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 2000; 1:489–495.PubMedCrossRefGoogle Scholar
  51. 51.
    Matsumura H, Shimizu Y, Ohsawa Y et al. Necrotic death pathway in Fas receptor signaling. J Cell Biol 2000; 151:1247–1256.PubMedCrossRefGoogle Scholar
  52. 52.
    Vercammen D, Brouckaert G, Denecker G et al. Dual signaling of the Fas receptor: Initiation of both apoptotic and necrotic cell death pathways. J Exp Med 1998; 188:919–930.PubMedCrossRefGoogle Scholar
  53. 53.
    Berghe TV, van Loo G, Saelens X et al. Differential signaling to apoptotic and necrotic cell death by Fas-associated death domain protein FADD. J Biol Chem 2004; 279:7925–7933.CrossRefGoogle Scholar
  54. 54.
    Kreuz S, Siegmund D, Rumpf JJ et al. NFkappaB activation by Fas is mediated through FADD, caspase-8 and RIP and is inhibited by FLIP. J Cell Biol 2004; 166:369–380.PubMedCrossRefGoogle Scholar
  55. 55.
    Hu WH, Johnson H, Shu HB. Activation of NF-kappaB by FADD, Casper and caspase-8. J Biol Chem 2000; 275:10838–10844.PubMedCrossRefGoogle Scholar
  56. 56.
    Wajant H, Haas E, Schwenzer R et al. Inhibition of death receptor-mediated gene induction by a cycloheximide-sensitive factor occurs at the level of or upstream of Fas-associated death domain protein (FADD). J Biol Chem 2000; 275:24357–24366.PubMedCrossRefGoogle Scholar
  57. 57.
    Chaudhary PM, Eby MT, Jasmin A et al. Activation of the NF-kappaB pathway by caspase 8 and its homologs. Oncogene 2000; 19:4451–4460.PubMedCrossRefGoogle Scholar
  58. 58.
    Cardone MH, Salvesen GS, Widmann C et al. The regulation of anoikis: MEKK-1 activation requires cleavage by caspases. Cell 1997; 90:315–323.PubMedCrossRefGoogle Scholar
  59. 59.
    Widmann C, Gerwins P, Johnson NL et al. MEK kinase 1, a substrate for DEVD-directed caspases, is involved in genotoxin-induced apoptosis. Mol Cell Biol 1998; 18:2416–2429.PubMedGoogle Scholar
  60. 60.
    Widmann C, Johnson NL, Gardner AM et al. Potentiation of apoptosis by low dose stress stimuli in cells expressing activated MEK kinase 1. Oncogene 1997; 15:2439–2447.PubMedCrossRefGoogle Scholar
  61. 61.
    Ham YM, Choi JS, Chun KH et al. The c-Jun N-terminal kinase 1 activity is differentially regulated by specific mechanisms during apoptosis. J Biol Chem 2003; 278:50330–50337.PubMedCrossRefGoogle Scholar
  62. 62.
    Low W, Smith A, Ashworth A et al. JNK activation is not required for Fas-mediated apoptosis. Oncogene 1999; 18:3737–3741.PubMedCrossRefGoogle Scholar
  63. 63.
    Lenczowski JM, Dominguez L, Eder AM et al. Lack of a role for Jun kinase and AP-1 in Fas-induced apoptosis. Mol Cell Biol 1997; 17:170–181.PubMedGoogle Scholar
  64. 64.
    Esposito G, Prasad SV, Rapacciuolo A et al. Cardiac overexpression of a G(q) inhibitor blocks induction of extracellular signal-regulated kinase and c-Jun NH(2)-terminal kinase activity in in vivo pressure overload. Circulation 2001; 103:1453–1458.PubMedGoogle Scholar
  65. 65.
    Choukroun G, Hajjar R, Fry S et al. Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH(2)-terminal kinases. J Clin Invest 1999 104:391–398.PubMedCrossRefGoogle Scholar
  66. 66.
    Badorff C ruetten H, Mueller S et al. Fas receptor signaling inhibits glycogen synthase kinase 3 beta and induces cardiac hypertrophy following pressure overload. J Clin Invest 2002; 109:373–381.PubMedGoogle Scholar
  67. 67.
    Cross DA, Alessi DR, Cohen P et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378:785–789.PubMedCrossRefGoogle Scholar
  68. 68.
    Alderson MR, Armitage RJ Maraskovsky E et al. Fas transduces activation signals in normal human T-lymphocytes. J Exp Med 1993; 178:2231–2235.PubMedCrossRefGoogle Scholar
  69. 69.
    Kurasawa K, Hashimoto Y, Kasai M et al. The Fas antigen is involved in thymic T-cell development as a costimulatory molecule, but not in the deletion of neglected thymocytes. J Allergy Clin Immunol 2000; 106:S19–S31.PubMedCrossRefGoogle Scholar
  70. 70.
    Sun M, Fink PJ. A new class of reverse signaling costimulators belongs to the TNF family. J Immunol 2007; 179:4307–4312.PubMedGoogle Scholar
  71. 71.
    Aggarwal BB, Singh S, LaPushin R et al. Fas antigen signals proliferation of normal human diploid fibroblast and its mechanism is different from tumor necrosis factor receptor. FEBS Lett 1995; 364:5–8.PubMedCrossRefGoogle Scholar
  72. 72.
    Freiberg RA, Spencer DM, Choate KA, et al. Fas signal transduction triggers either proliferation or apoptosis in human fibroblasts. J Invest Dermatol 1997; 108:215–219.PubMedCrossRefGoogle Scholar
  73. 73.
    Ahn JH, Park SM, Cho HS et al. Non-apoptotic signaling pathways activated by soluble Fas ligand in serum-starved human fibroblasts. Mitogen-activated protein kinases and NF-kappaB-dependent gene expression. J Biol Chem 2001; 276:47100–47106.PubMedCrossRefGoogle Scholar
  74. 74.
    Desbarats J, Newell MK. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat Med 2000; 6:920–923.PubMedCrossRefGoogle Scholar
  75. 75.
    Ma Y, Liu H, Tu-Rapp H et al. Fas ligation on macrophages enhances IL-1R1-Toll-like receptor 4 signaling and promotes, chronic inflammation. Nat Immunol 2004; 5:380–387.PubMedCrossRefGoogle Scholar
  76. 76.
    Griffith TS, Brunner T, Fletcher SM et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270:1189–1192.PubMedCrossRefGoogle Scholar
  77. 77.
    Sabelko-Downes KA, Cross AH, Russell JH. Dual role for Fas ligand in the initiation of and recovery from experimental allergic encephalomyelitis. J Exp Med 1999; 189:1195–1205.PubMedCrossRefGoogle Scholar
  78. 78.
    Suvannavejh GC, Dal Canto MC, Matis LA et al. Fas-mediated apoptosis in clinical remissions of relapsing experimental autoimmune encephalomyelitis. J Clin Invest 2000; 105:223–231.PubMedCrossRefGoogle Scholar
  79. 79.
    Gochuico BR, Miranda KM, Hessel EM et al. Airway epithelial Fas ligand expression: potential role in modulating bronchial inflammation. Am J Physiol Lung Cell Mol Physiol 1998; 274:L444–L449.Google Scholar
  80. 80.
    Hunt JS, Vassmer D, Ferguson TA et al. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J Immunol 1997; 158:4122–4128.PubMedGoogle Scholar
  81. 81.
    Bohana-Kashtan O, Civin CI. Fas ligand as a tool for immunosuppression and generation of immune tolerance. Stem Cells 2004; 22:908–924.PubMedCrossRefGoogle Scholar
  82. 82.
    Kang SM, Schneider DB, Lin Z et al. Fas ligand expression in islets of langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997; 3:738–743.PubMedCrossRefGoogle Scholar
  83. 83.
    Takeuchi T, Ueki T, Nishimatsu H et al. Accelerated rejection of Fas ligand-expressing heart grafts. J Immunol 1999; 162:518–522.PubMedGoogle Scholar
  84. 84.
    Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991; 9:243–269.PubMedCrossRefGoogle Scholar
  85. 85.
    Watanabe-Fukunaga R, Brannan CI, Copeland NG et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356:314–317.PubMedCrossRefGoogle Scholar
  86. 86.
    Kennedy NJ, Kataoka T, Tschopp J et al. Caspase activation is required for T-cell proliferation. J Exp Med 1999; 190:1891–1896.PubMedCrossRefGoogle Scholar
  87. 87.
    Alam A, Cohen LY, Aouad S et al. Early activation of caspases during T-lymphocyte stimulation, results in selective substrate cleavage in nonapoptotic cells. J Exp Med 1999; 190:1879–1890.PubMedCrossRefGoogle Scholar
  88. 88.
    Mack A, Hacker G. Inhibition of caspase or FADD function blocks proliferation but not MAP kinase-activation and interleukin-2-production during primary stimulation, of T-cells. Eur J Immunol 2002; 32:1986–1992.PubMedCrossRefGoogle Scholar
  89. 89.
    Beisner DR, Chu IH, Arechiga AF et al. The requirements for Fas-associated death domain signaling in mature T-cell activation and survival. J Immunol 2003; 171:247–256.PubMedGoogle Scholar
  90. 90.
    Chun HJ, Zheng L, Ahmad, M et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 2002; 419:395–399.PubMedCrossRefGoogle Scholar
  91. 91.
    Green DR, Droin N, Pinkoski M. Activation-induced cell death in T-cells. Immunol Rev 2003; 193:70–81.PubMedCrossRefGoogle Scholar
  92. 92.
    Rieux-Laucat F, Le Deist F, Fischer A. Autoimmune lymphoproliferative syndromes: Genetic defects of apoptosis pathways. Cell Death Differ 2003; 10:124–133.PubMedCrossRefGoogle Scholar
  93. 93.
    Reap EA, Felix NJ, Wolthusen PA et al. bcl-2 transgenic Lpr mice show profound enhancement of lymphadenopathy. J. Immunol 1995; 155:5455–5462.PubMedGoogle Scholar
  94. 94.
    Strasser A, Harris AW, Huang DC et al. Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J 1995; 14:6136–6147.PubMedGoogle Scholar
  95. 95.
    Hildeman DA, Zhu Y, Mitchell TC et al. Activated T-cell death in vivo mediated by proapoptotic bcl-2 family member bim. Immunity 2002; 16:759–767.PubMedCrossRefGoogle Scholar
  96. 96.
    Lu B, Finn OJ. T-cell death and cancer immune tolerance. Cell Death Differ 2007; 15:70–79.PubMedCrossRefGoogle Scholar
  97. 97.
    Hughes PD, Belz GT, Fortner KA et al. Apoptosis regulators Fas and bim cooperate in shutdown of chronic immune responses and prevention of autoimmunity. Immunity 2008; 28:197–205.PubMedCrossRefGoogle Scholar
  98. 98.
    Hutcheson J, Scatizzi JC, Siddiqui AM et al. Combined deficiency of proapoptotic regulators bim and Fas results in the early onset of systemic autoimmunity. Immunity 2008; 28:206–217.PubMedCrossRefGoogle Scholar
  99. 99.
    Weant AE, Michalek RD, Khan IU et al. Apoptosis regulators bim and fas function concurrently to control autoimmunity and CD8(+) T-cell contraction. Immunity 2008; 28:218–230.PubMedCrossRefGoogle Scholar
  100. 100.
    Green DR. Fas Bim Boom. Immunity 2008; 28:141–143.PubMedCrossRefGoogle Scholar
  101. 101.
    Takahashi T, Tanaka M, Brannan CI et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76:969–976.PubMedCrossRefGoogle Scholar
  102. 102.
    Siegel RM, Chan FK, Chun HJ et al. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol 2000; 1:469–474.PubMedCrossRefGoogle Scholar
  103. 103.
    Schumann DM, Maedler K, Franklin I et al. The Fas pathway is involved in pancreatic beta cell secretory function. Proc Natl Acad Sci USA 2007; 104:2861–2866.PubMedCrossRefGoogle Scholar
  104. 104.
    Maedler K, Spinas GA, Lehmann R et al. Glucose induces ta-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes 2001; 50:1683–1690.PubMedCrossRefGoogle Scholar
  105. 105.
    Donath MY, Storling J, Maedler K et al. Inflammatory mediators and islet beta-cell failure: A link between type 1 and type 2 diabetes. J Mol Med 2003; 81:455–470.PubMedCrossRefGoogle Scholar
  106. 106.
    Surh CD, Sprent J. T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 1994; 372:100–103.PubMedCrossRefGoogle Scholar
  107. 107.
    Castro JE, Listman JA, Jacobson, BA et al. Fas modulation of apoptosis during negative selection of thymocytes. Immunity 1996; 5:617–627.PubMedCrossRefGoogle Scholar
  108. 108.
    Singer GG, Abbas AK. The Fas antigen is involved in peripheral but not thymic deletion of T-lymphocytes in T-cell receptor transgenic mice. Immunity 1994; 1:365–371.PubMedCrossRefGoogle Scholar
  109. 109.
    Bidere N, Su HC, Lenardo MJ. Genetic disorders of programmed cell death in the immune system. Annu Rev Immunol 2006; 24:321–352.PubMedCrossRefGoogle Scholar
  110. 110.
    Sneller MC, Dale JK, Straus SE. Autoimmune lymphoproliferative syndrome. Curr Opin Rheumatol 2003; 15:417–421.PubMedCrossRefGoogle Scholar
  111. 111.
    Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol 2007; 56:181–200.PubMedCrossRefGoogle Scholar
  112. 112.
    Viard I, Wehrli P, Bullani R et al. Inhibition, of toxic epidermal necrolysis by blockade of cd95 with human intravenous immunoglobulin. Science 1998; 282:490–493.PubMedCrossRefGoogle Scholar
  113. 113.
    Paquet P, Pierard GE, Quatresooz P. Novel treatments for drug-induced toxic epidermal necrolysis (Lyell’s syndrome). Int Arch Allergy Immunol 2005; 136:205–216.PubMedCrossRefGoogle Scholar
  114. 114.
    Ferguson TA, Griffith TS. A vision, of cell death: Fas ligand and immune, privilege 10 years later. Immunol Rev 2006; 213:228–238.PubMedCrossRefGoogle Scholar
  115. 115.
    Stuart PM, Griffith TS, Usui N et al. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest 1997; 99:396–402.PubMedCrossRefGoogle Scholar
  116. 116.
    Griffith TS, Yu X, Herndon JM et al. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological to lerance. Immunity 1996; 5:7–16.PubMedCrossRefGoogle Scholar
  117. 117.
    Hu MS, Schwartzman JD, Yeaman GR et al. Fas-FasL interaction involved in pathogenesis of ocular toxoplasmosis in mice. Infect Immun 1999; 67:928–935.PubMedGoogle Scholar
  118. 118.
    Yamagami S, Kawashima H, Tsuru T et al. Role of Fas-Fas ligand interactions in the immunorejection of allogeneic mouse corneal transplants. Transplantation 1997; 64:1107–1111.PubMedCrossRefGoogle Scholar
  119. 119.
    Filippatos G, Leche C, Sunga R et al. Expression of FAS adjacent to fibrotic foci in the failing human heart is not associated with increased apoptosis. Am J Physiol 1999; 277:H445–H451.PubMedGoogle Scholar
  120. 120.
    Perez EC, Shulzhenko N, Morgun A et al. Expression of Fas, Fasl and soluble Fas mrna in endomyocardial biopsies of human cardiac allografts. Human Immunology 2006; 67:22–26.PubMedCrossRefGoogle Scholar
  121. 121.
    Askenasy N, Yolcu ES, Wang Z et al. Display of Fas ligand protein on cardiac vasculature as a novel means of regulating allograft rejection. Circulation 2003; 107:1525–1531.PubMedCrossRefGoogle Scholar
  122. 122.
    Yang J, Jones SP Suhara T et al. Endothelial cell overexpression of Fas ligand attenuates ischemia-reperfusion injury in the heart. J Biol Chem 2003; 278:15185–15191.PubMedCrossRefGoogle Scholar
  123. 123.
    Kanamori H, Takemura G, Li Y et al. Inhibition of Fas-associated apoptosis in granulation tissue cells accompanies attenuation of postinfarction left ventricular remodeling by olmesartan. Am J Physiol Heart Circ Physiol 2007; 292:H2184–H2194.PubMedCrossRefGoogle Scholar
  124. 124.
    Higuchi MD, Ries MM, Aiello VD et al. Association of an increase in CD8+ T-cells with the presence of Trypanosoma cruzi antigens in chronic, human, chagasic myocarditis. Am J Trop Med Hyg 1997; 56:485–489.PubMedGoogle Scholar
  125. 125.
    Tostes S Jr, Bertulucci Rocha-Rodrigues D, de Araujo PG et al. Myocardiocyte apoptosis in heart failure in chronic Chagas’ disease. Int J Cardiol 2005; 99:233–237.PubMedCrossRefGoogle Scholar
  126. 126.
    de Oliveira GM, Diniz RL, Batista W et al. Fas ligand-dependent inflammatory regulation in acute myocarditis induced by Trypanosoma cruzi infection. Am J Pathol 2007; 171:79–86.PubMedCrossRefGoogle Scholar
  127. 127.
    Guillermo LV, Silva EM, Ribeiro-Gomes FL et al. The Fas death pathway controls coordinated expansions of type 1 CD8 and type 2 CD4 T-cells in Trypanosoma cruzi infection. J Leukoc Biol 2007; 81:942–951.PubMedCrossRefGoogle Scholar
  128. 128.
    Niu J, Azfer A, Kolattukudy PE. Protection, against lipopolysacharide-induced myocardial dysfunction in mice by cardiac-specific expression of soluble Fas. J Mol Cell Cardiol 2008; 44:160–169.PubMedCrossRefGoogle Scholar
  129. 129.
    Volpert OV, Zaichuk T, Zhou W et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002; 8:349–357.PubMedCrossRefGoogle Scholar
  130. 130.
    Lucas R, Holmgren L, Garcia I et al. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 1998; 92:4730–4741.PubMedGoogle Scholar
  131. 131.
    Jimenez B, Volpert OV, Crawford SE et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000; 6:41–48.PubMedCrossRefGoogle Scholar
  132. 132.
    Stellmach V, Crawford SE, Zhou W et al. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci USA. 2001; 98:2593–2597.PubMedCrossRefGoogle Scholar
  133. 133.
    Zaichuk TA, Shroff EH, Emmanuel R et al. Nuclear factor of activated, T-cells balances angiogenesis activation and inhibition. J Exp Med 2004; 199:1513–1522.PubMedCrossRefGoogle Scholar
  134. 134.
    Kamphaus GD, Colorado PC, Panka DJ et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 2000; 275:1209–1215.PubMedCrossRefGoogle Scholar
  135. 135.
    Panka DJ, Mier JW. Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J Biol Chem 2003; 278:37632–37636.PubMedCrossRefGoogle Scholar
  136. 136.
    Choi C, Benveniste EN., Fas ligand/Fas system in the brain: regulator of immune and apoptotic responses. Brain Res Rev 2004; 44:65–81.PubMedCrossRefGoogle Scholar
  137. 137.
    Shin DH, Lee E, Kim HJ et al. Fas ligand mRNA expression in the mouse central nervous system. Journal of Neuroimmunology 2002; 123:50–57.PubMedCrossRefGoogle Scholar
  138. 138.
    Park C, Sakamaki K, Tachibana O et al. Expression of Fas Antigen in the Normal Mouse Brain. Biochem Biophys Res Commun 1998; 252:623–628.PubMedCrossRefGoogle Scholar
  139. 139.
    Raoul C, Henderson CE, Pettmann B. Programmed cell death of embryonic motoneurons triggered through the Fas death receptor. J Cell Biol 1999; 147:1049–1062.PubMedCrossRefGoogle Scholar
  140. 140.
    Raoul C, Estevez AG, Nishimune H et al. Motoneuron death triggered by a specific pathway downstream of Fas. potentiation by ALS-linked SOD1 mutations. Neuron 2002; 35:1067–1083.PubMedCrossRefGoogle Scholar
  141. 141.
    Desbarats J, Birge RB, Mimouni-Rongy M et al. Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat Cell Biol 2003; 5:118–125.PubMedCrossRefGoogle Scholar
  142. 142.
    Pettmann B, Henderson CE. Killer wiles: Growing interest in Fas. Nat, Cell Biol 2003; 5:91–92.CrossRefGoogle Scholar
  143. 143.
    Lambert C, Landau AM, Desbarats J. Fas-beyond death: A regenerative role for Fas in the nervous system. Apoptosis 2003; 8:551–562.PubMedCrossRefGoogle Scholar
  144. 144.
    Ruckenstein MJ, Milburn M, Hu L. Strial dysfunction in the MRL-Fas mouse. Otolaryngol Head Neck Surg 1999; 121:452–456.PubMedCrossRefGoogle Scholar
  145. 145.
    Ruckenstein MJ, Sarwar A, Hu L et al. Effects of immunosuppression on the development of cochlear disease in the MRL-Fas(lpr) mouse. Laryngoscope 1999; 109:626–630.PubMedCrossRefGoogle Scholar
  146. 146.
    Hess DC, Taormina M, Thompson J et al. Cognitive and neurologic deficits in the MRL/lpr mouse: a clinicopathologic study. J Rheumatol 1993; 20:610–617.PubMedGoogle Scholar
  147. 147.
    Fernandez M, Segura MF, Sole C et al. Lifeguard/neuronal membrane protein 35 regulates Fas ligand-mediated apoptosis in neurons via microdomain recruitment. J Neurochem 2007; 103:190–203.PubMedGoogle Scholar
  148. 148.
    Somia NV, Schmitt MJ, Vetter DE et al. LFG: An anti-apoptotic gene that provides protection from Fas-mediated cell death. Proc Natl Acad Sci USA 1999; 96:12667–12672.PubMedCrossRefGoogle Scholar
  149. 149.
    Segura MF, Sole C, Pascual M et al. The long form of Fas apoptotic inhibitory molecule is expressed specifically in neurons and protects them against death receptor-triggered apoptosis. J Neurosci 2007; 27:11228–11241.PubMedCrossRefGoogle Scholar
  150. 150.
    Demjen D, Klussmann S, Kleber S et al. Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury. Nat Med 2004; 10:389–395.PubMedCrossRefGoogle Scholar
  151. 151.
    Casha S, Yu WR, Fehlings MG. FAS deficiency reduces apoptosis, spares axons and improves function after spinal cord injury. Exp Neurol 2005; 196:390–400.PubMedCrossRefGoogle Scholar
  152. 152.
    Yoshino O, Matsuno H, Nakamura H et al. The role of Fas-mediated apoptosis after traumatic spinal cord injury. Spine 2004; 29:1394–1404.PubMedCrossRefGoogle Scholar
  153. 153.
    Ackery A, Robins S, Fehlings MG. Inhibition of Fas-mediated apoptosis through administration of soluble Fas receptor improves functional outcome and reduces posttraumatic axonal degeneration after acute spinal cord injury. J Neurotrauma 2006; 23:604–616.PubMedCrossRefGoogle Scholar
  154. 154.
    Ugolini G, Raoul C, Ferri A et al. Fas/tumor necrosis factor receptor death signaling is required for axotomy-induced death of motoneurons in vivo. J Neurosci 2003; 23:8526–8531.PubMedGoogle Scholar
  155. 155.
    Martin-Villalba A, Herr I, Jeremias I et al. CD95 Ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J Neurosci 1999; 19:3809–3817.PubMedGoogle Scholar
  156. 156.
    Martin-Villalba A, Hahne M, Kleber S et al. Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ 2001; 8:679–686.PubMedCrossRefGoogle Scholar
  157. 157.
    Graham EM, Sheldon RA, Flock DL et al. Neonatal mice lacking functional Fas death receptors are resistant to hypoxic-ischemic brain injury. Neurobiol Dis 2004; 17:89–98.PubMedCrossRefGoogle Scholar
  158. 158.
    Raoul C, Barthelemy C, Couzinet A et al. Expression of a dominant negative form of Daxx in vivo rescues motoneurons from Fas (CD95)-induced cell death. J Neurobiol 2005; 62:178–188.PubMedCrossRefGoogle Scholar
  159. 159.
    Dasari VR, Spomar DG, Li L et al. Umbilical cord blood stem cell mediated downregulation of Fas improves functional recovery of rats after spinal cord injury. Neurochem Res 2008; 33:134–149.PubMedCrossRefGoogle Scholar
  160. 160.
    McFarland HF, Martin R. Multiple sclerosis: A complicated picture of autoimmunity. Nat Immunol 2007; 8:913–919.PubMedCrossRefGoogle Scholar
  161. 161.
    Diem R, Sattler MB, Bahr M. Neurodegeneration and-protection in autoimmune CNS in flammation. J Neuroimmunol 2007; 184:27–36.PubMedCrossRefGoogle Scholar
  162. 162.
    Fox EJ. Immunopathology of multiple sclerosis. Neurology 2004; 63:S3–S7.PubMedGoogle Scholar
  163. 163.
    Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 2002; 3:291–301.PubMedCrossRefGoogle Scholar
  164. 164.
    Aktas O, Prozorovski T, Zipp F. Death ligands and autoimmune demyelination. Neuroscientist 2006; 12:305–316.PubMedCrossRefGoogle Scholar
  165. 165.
    Wildbaum G, Westermann J, Maor G et al. A targeted DNA vaccine encoding Fas ligand defines its dual role in the regulation of experimental autoimmune encephalomyelitis. J Clin Invest 2000; 106:671–679.PubMedCrossRefGoogle Scholar
  166. 166.
    Okuda Y, Sakoda S, Fujimura H et al. Intrathecal administration of neutralizing antibody against Fas ligand suppresses the progression of experimental autoimmune encephalomyelitis. Biochem Biophys Res Commun 2000; 275:164–168.PubMedCrossRefGoogle Scholar
  167. 167.
    Ciusani E, Gelati M, Frigerio S et al. Modulation of experimental allergic encephalomyelitis in Lewis rats by administration of a peptide of Fas ligand. J Autoimmun 2001; 17:273–280.PubMedCrossRefGoogle Scholar
  168. 168.
    Zhu B, Luo L, Chen Y et al. Intrathecal Fas ligand infusion strengthens immunoprivilege of central nervous system and suppresses experimental autoimmune encephalomyelitis. J Immunol 2002; 169:1561–1569.PubMedGoogle Scholar
  169. 169.
    Ni R, Tomita Y, Matsuda K et al. Fas-mediated apoptosis in primary cultured mouse hepatocytes. Exp Cell Res 1994; 215:332–337.PubMedCrossRefGoogle Scholar
  170. 170.
    Galle PR, Hofmann WJ, Walczak H et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995; 182:1223–1230.PubMedCrossRefGoogle Scholar
  171. 171.
    Ueno Y, Ishii M, Yahagi K et al. Fas-mediated cholangiopathy in the murine model of graft versus host disease. Hepatology 2000; 31:966–974.PubMedCrossRefGoogle Scholar
  172. 172.
    Cardier JE, Schulte T, Kammer H et al. Fas (CD95, APO-1) antigen expression and function in murine liver endothelial cells: implications for the regulation of apoptosis in liver endothelial cells. FASEB J 1999; 13:1950–1960.PubMedGoogle Scholar
  173. 173.
    Saile B, Knittel T, Matthes N et al. CD95/CD95L-mediated apoptosis of the hepatic stellate cell. A mechanism terminating uncontrolled hepatic stellate cell proliferation during hepatic tissue repair. Am J Pathol 1997; 151:1265–1272.PubMedGoogle Scholar
  174. 174.
    Muschen M, Warskulat U, Douillard P et al. Regulation of CD95 (APO-1/Fas) receptor and ligand expression by lipopolysaccharide and dexamethasone in parenchymal and nonparenchymal rat liver cells. Hepatology 1998; 27:200–208.PubMedCrossRefGoogle Scholar
  175. 175.
    Bennett M, Macdonald K, Chan SW et al. Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis. Science 1998; 282:290–293.PubMedCrossRefGoogle Scholar
  176. 176.
    Sodeman T, Bronk SF, Roberts PJ et al. Bile salts mediate hepatocyte apoptosis by increasing cell surface trafficking of Fas. Am J Physiol Gastrointest Liver Physiol 2000; 278:G992–G999.PubMedGoogle Scholar
  177. 177.
    Chan H, Bartos DP, Owen-Schaub LB. Activation-dependent transcriptional regulation of the human Fas promoter requires NF-kappaB p50-p65 recruitment. Mol Cell Biol 1999; 19:2098–2108.PubMedGoogle Scholar
  178. 178.
    Peter ME, Hellbardt S, Schwartz-Albiez R et al. Cell surface sialylation plays a role in modulating sensitivity towards APO-1-mediated apoptotic cell death. Cell Death Differ 1995; 2:163–171.PubMedGoogle Scholar
  179. 179.
    Sun Z, Wada T, Maemura K et al. Hepatic allograft-derived Kupffer cells regulate T-cell response in rats. Liver Transpl 2003; 9:489–497.PubMedCrossRefGoogle Scholar
  180. 180.
    Adachi M, Suematsu S, Kondo T et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet 1995; 11:294–300.PubMedCrossRefGoogle Scholar
  181. 181.
    Kataoka T, Budd RC, Holler N et al. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr Biol 2000; 10:640–648.PubMedCrossRefGoogle Scholar
  182. 182.
    Canbay A, Friedman S, Gores GJ. Apoptosis: The nexus of liver injury and fibrosis. Hepatology 2004; 39:273–278.PubMedCrossRefGoogle Scholar
  183. 183.
    Canbay A, Higuchi H, Bronk SF et al. Fas enhances fibrogenesis in the bile duct ligated mouse: A link between apoptosis and fibrosis. Gastroenterology 2002; 123:1323–1330.PubMedCrossRefGoogle Scholar
  184. 184.
    Canbay A, Taimr P, Torok N et al. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003; 83:655–663.PubMedGoogle Scholar
  185. 185.
    Platt N, da Silva RP, Gordon S. Recognizing death: The phagocytosis of apoptotic cells. Trends Cell Biol 1998; 8:365–372.PubMedCrossRefGoogle Scholar
  186. 186.
    Houston A, O’Connell J. The Fas signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol 2004; 4:321–326.PubMedCrossRefGoogle Scholar
  187. 187.
    Stagg J, Johnstone RW, Smyth MJ. From cancer immunosurveillance to cancer immunotherapy. Immunol Rev 1007; 220:82–101.CrossRefGoogle Scholar
  188. 188.
    Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007; 117:1137–1146.PubMedCrossRefGoogle Scholar
  189. 189.
    Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006; 90:1–50.PubMedCrossRefGoogle Scholar
  190. 190.
    Wajant H, Pfizenmaier K, Scheurich P. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis 2002; 7:449–459.PubMedCrossRefGoogle Scholar
  191. 191.
    Wajant H CD95L/FasL and TRAIL in tumour surveillance and cancer therapy. Cancer Treat Res 2006; 130:141–65:141–165.PubMedCrossRefGoogle Scholar
  192. 192.
    Davidson WF, Giese T, Fredrickson TN. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J Exp Med 1998; 187:1825–1838.PubMedCrossRefGoogle Scholar
  193. 193.
    Zornig M, Grzeschiczek A, Kowalski MB et al. Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E mu L-MYC transgenic mice but not in animals infected with MoMuLV. Oncogene 1995; 10:2397–2401.PubMedGoogle Scholar
  194. 194.
    Peng SL, Robert ME, Hayday AC et al. A tumor-suppressor function for Fas (CD95) revealed in T-cell-deficient mice. J Exp Med 1996; 184:1149–1154.PubMedCrossRefGoogle Scholar
  195. 195.
    Zhang B, Sun T, Xue L et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 2007; 28:1067–1073.PubMedCrossRefGoogle Scholar
  196. 196.
    Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22:329–360.PubMedCrossRefGoogle Scholar
  197. 197.
    Mellor AL, Munn DH. Creating immune privilege: Active local suppression that benefits friends, but protects foes. Nat Rev Immunol 2008; 8:74–80.PubMedCrossRefGoogle Scholar
  198. 198.
    O’Connell J, O’Sullivan GC, Collins JK et al. The Fas counterattack: Fas-mediated T-cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184:1075–1082.PubMedCrossRefGoogle Scholar
  199. 199.
    Ryan AE, Lane S, Shanahan F et al. Fas ligand expression in human and mouse cancer cell lines; a caveat on over-reliance on mRNA data. J Carcinog 2006; 5:5.PubMedCrossRefGoogle Scholar
  200. 200.
    Yu JS, Lee PK, Ehtesham M et al. Intratumoral T-cell subset ratios and Fas ligand expression on brain tumor endothelium. J Neurooncol 2003; 64:55–61.PubMedGoogle Scholar
  201. 201.
    Ho SY, Guo HR, Chen HH et al. Prognostic implications of Fas-ligand expression in nasopharyngeal carcinoma. Head Neck 2004; 26:977–983.PubMedCrossRefGoogle Scholar
  202. 202.
    Krishnakumar S, Kandalam M, Mohan A et al. Expression of Fas ligand in retinoblastoma. Cancer 2004; 101:1672–1676.PubMedCrossRefGoogle Scholar
  203. 203.
    Ryan AE, Shanahan F, O’Connell J et al. Fas ligand promotes tumor immune evasion of colon cancer in vivo. Cell Cycle 2006; 5:246–249.PubMedGoogle Scholar
  204. 204.
    Okada K, Komuta K, Hashimoto S et al. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by Fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin Cancer Res 2000; 6:3560–3564.PubMedGoogle Scholar
  205. 205.
    Bennett MW, O’Connell J, O’Sullivan GC et al. The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998; 160:5669–5675.PubMedGoogle Scholar
  206. 206.
    Vogel A, Aslan JE, Willenbring H et al. Sustained phosphorylation of Bid is a marker for resistance to Fas-induced apoptosis during chronic liver diseases. Gastroenterology 2006; 130:104–119.PubMedCrossRefGoogle Scholar
  207. 207.
    Chida Y, Sudo N, Takaki A et al. The hepatic sympathetic nerve plays a critical role in preventing Fas induced liver injury in mice. Gut 2005; 54:994–1002.PubMedCrossRefGoogle Scholar
  208. 208.
    Stohl W, Xu D, Starling GC et al. Promotion of activated human B-cell apoptosis and inhibition of Ig production by soluble CD95 ligand: CD95-based down regulation of Ig production need not culminate in activated B-cell death. Cell Immunol 2000; 203:1–11.PubMedCrossRefGoogle Scholar
  209. 209.
    Lepple-Wienhues A, Belka C, Laun T et al. Stimulation of CD95 (Fas) blocks T-lymphocyte calcium channels through sphingomyelinase and sphingolipids. Proc Natl Acad Sci USA. 1999; 96:13795–13800.PubMedCrossRefGoogle Scholar
  210. 210.
    Li H, Cai X, Fan X et al. Fas Ag-FasL coupling leads to ERK1/2-mediated proliferation of gastric mucosal cells. Am J Physiol Gastrointest Liver Physiol 2008; 294:G263–G275.PubMedCrossRefGoogle Scholar
  211. 211.
    Mitsiades CS, Poulaki V, Fanourakis G et al. Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin Cancer Res 2006; 12:3705–3712.PubMedCrossRefGoogle Scholar
  212. 212.
    Houston A, Waldron-Lynch FD, Bennett MW et al. Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo. Int J Cancer 2003; 107:209–214.PubMedCrossRefGoogle Scholar
  213. 213.
    Pitti RM, Marsters SA, Lawrence DA et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998; 396:699–703.PubMedCrossRefGoogle Scholar
  214. 214.
    Peshes-Yaloz N, Rosen D, Sondel PM et al. Up-regulation of Fas (CD95) expression in tumour cells in vivo. Immunology 2007; 120:502–511.PubMedCrossRefGoogle Scholar
  215. 215.
    Ivanov VN, Lopez BP, Maulit G et al. FAP-1 association with Fas (Apo-1) inhibits Fas expression on the cell surface. Mol Cell Biol 2003; 23:3623–3635.PubMedCrossRefGoogle Scholar
  216. 216.
    Huerta S, Heinzerling JH, Anguiano-Hernandez YM et al. Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO and AIF. J Surg Res 2007; 142:184–194.PubMedCrossRefGoogle Scholar
  217. 217.
    Wang L, Azad N, Kongkaneramit L et al. The Fas death signaling pathway connecting reactive oxygen species generation and FLICE inhibitory protein down-regulation. J Immunol 2008; 180:3072–3080.PubMedGoogle Scholar
  218. 218.
    Irmler M, Thome M, Hahne M et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388:190–195.PubMedCrossRefGoogle Scholar
  219. 219.
    Tourneur L, Mistou S, Michiels FM et al. Loss of FADD protein expression results in a biased Fas-signaling pathway and correlates with the development of tumoral status in thyroid follicular cells. Oncogene 2003; 22:2795–2804.PubMedCrossRefGoogle Scholar
  220. 220.
    Fulda S, Kufer MU, Meyer E et al. Sensitization for death receptor-or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001; 20:5865–5877.PubMedCrossRefGoogle Scholar
  221. 221.
    Hahne M, Rimoldi D, Schroter M et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274:1363–1366.PubMedCrossRefGoogle Scholar
  222. 222.
    Seino K, Kayagaki N, Okumura K et al. Antitumor effect of locally produced CD95 ligand. Nat Med 1997; 3:165–170.PubMedCrossRefGoogle Scholar
  223. 223.
    Arai H, Gordon D, Nabel EG et al. Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci USA. 1997; 94:13862–13867.PubMedCrossRefGoogle Scholar
  224. 224.
    Igney FH, Behrens CK, Krammer PH. CD95L mediates tumor counterattack in vitro but induces neutrophil-independent tumor rejection in vivo. Int J Cancer 2005; 113:78–87.PubMedCrossRefGoogle Scholar
  225. 225.
    Ryan AE, Shanahan F, O’Connell J et al. Addressing the “Fas counterattack” controversy: blocking Fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Cancer Res 2005; 65:9817–9823.PubMedCrossRefGoogle Scholar
  226. 226.
    Seino K, Kayagaki N, Fukao K et al. Rejection of Fas ligand-expressing grafts. Transplant Proc 1997; 29:1092–1093.PubMedCrossRefGoogle Scholar
  227. 227.
    Fingleton B, Carter KJ, Matrisian LM. Loss of functional Fas ligand enhances intestinal tumorigenesis in the min mouse model. Cancer Res 2007; 67:4800–4806.PubMedCrossRefGoogle Scholar
  228. 228.
    Hohlbaum AM, Gregory MS, Ju ST et al. Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors. J Immunol 2001; 167:6217–6224.PubMedGoogle Scholar
  229. 229.
    Hohlbaum AM, Moe S, Marshak-Rothstein A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med 2000; 191:1209–1220.PubMedCrossRefGoogle Scholar
  230. 230.
    Seino K, Ogino T, Fukunaga K et al. Attempts to reveal the mechanism of CD95-ligand-mediated inflammation. Transplant Proc 1999; 31:1942–1943.PubMedCrossRefGoogle Scholar
  231. 231.
    Park DR, Thomsen AR, Frevert CW et al. Fas (CD95) induces proinflammatory cytokine responses by human monocytes and monocyte-derived macrophages. J Immunol 2003; 170:6209–6216.PubMedGoogle Scholar
  232. 232.
    O’Connell J, Houston A, Bennett MW et al. Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat Med 2001; 7:271–274.PubMedCrossRefGoogle Scholar
  233. 233.
    Abrahams VM, Straszewski SL, Kamsteeg M et al. Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res 2003; 63:5573–5581.PubMedGoogle Scholar
  234. 234.
    Friesen C, Herr I, Krammer PH et al. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996; 2:574–577.PubMedCrossRefGoogle Scholar
  235. 235.
    Fulda S, Sieverts H, Friesen C et al. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997; 57:3823–3829.PubMedGoogle Scholar
  236. 236.
    Muller M, Strand S, Hug H et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997; 99:403–413.PubMedCrossRefGoogle Scholar
  237. 237.
    Zender L, Hutker S, Liedtke C et al. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci USA 2003; 100:7797–7802.PubMedCrossRefGoogle Scholar
  238. 238.
    Contreras JL, Vilatoba M, Eckstein C et al. Caspase-8 and caspase-3 small interfering RNA decreases ischemia/reperfusion injury to the liver in mice. Surgery 2004; 136:390–400.PubMedCrossRefGoogle Scholar
  239. 239.
    Song E, Lee SK, Wang J et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003; 9:347–351.PubMedCrossRefGoogle Scholar
  240. 240.
    Wong M, Ziring D, Korin Y et al. TNF alpha blockade in human diseases: Mechanisms and future directions. Clin Immunol 2008; 126:121–136.PubMedCrossRefGoogle Scholar
  241. 241.
    Schwarz EM, Ritchlin CT. Clinical development of anti-RANKL therapy. Arthritis Res Ther 2007; 9(Suppl 1):S7.CrossRefGoogle Scholar
  242. 242.
    Dillon SR, Gross JA, Ansell SM et al. An APRIL to remember: Novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006; 5:235–246.PubMedCrossRefGoogle Scholar
  243. 243.
    Tanaka M, Suda T, Haze K et al. Fas ligand in human serum. Nat Med 1996; 2:317–322.PubMedCrossRefGoogle Scholar
  244. 244.
    Miwa K, Hashimoto H, Yatomi T et al. Therapeutic effect of an anti-Fas ligand mAb on lethal graft-versus-host disease. Int Immunol 1999; 11:925–931.PubMedCrossRefGoogle Scholar
  245. 245.
    Holler N, Kataoka T, Bodmer JL et al. Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors. J Immunol Methods 2000; 237:159–173.PubMedCrossRefGoogle Scholar
  246. 246.
    Watermann I, Gerspach J, Lehne M et al. Activation of CD95L fusion protein prodrugs by tumor-associated proteases. Cell Death Differ 2006; 14:765–774.PubMedCrossRefGoogle Scholar
  247. 247.
    Farley SM, Purdy DE, Ryabinina OP et al. Fas ligand-induced proin flammatory transcriptional responses in reconstructed human epidermis. Recruitment of the epidermal growth factor receptor and activation of MAP kinases. J Biol Chem 2008; 283:919–928.PubMedCrossRefGoogle Scholar
  248. 248.
    Yu KY, Kwon B, Ni J et al. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 1999; 274:13733–13736.PubMedCrossRefGoogle Scholar
  249. 249.
    Migone TS, Zhang J, Luo X et al. TL1A Is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T-cell costimulator. Immunity 2002; 16:479–492.PubMedCrossRefGoogle Scholar
  250. 250.
    Wroblewski VJ, McCloud C, Davis K et al. Pharmacokinetics, metabolic stability and subcutaneous u bioavailability of a genetically engineered analog of DcR3, FLINT [DcR3(R218Q)], in cynomolgus monkeys and mice. Drug Metab Dispos 2003; 31:502–507.PubMedCrossRefGoogle Scholar
  251. 251.
    Wortinger MA, Foley JW, Larocque P et al. Fas ligand-induced murine pulmonary inflammation is reduced by a stable decoy receptor 3 analogue. Immunology 2003; 110:225–233.PubMedCrossRefGoogle Scholar
  252. 252.
    Holler N, Tardivel A, Kovacsovics-Bankowski M et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol 2003; 23:1428–1440.PubMedCrossRefGoogle Scholar
  253. 253.
    Schmidt M, Lugering N, Pauels HG et al. IL-10 induces apoptosis in human monocytes involving the CD95 receptor/ligand pathway. Eur J Immunol 2000; 30:1769–1777.PubMedCrossRefGoogle Scholar
  254. 254.
    Schmidt M, Lugering N, Lugering A et al. Role of the CD95/CD95 ligand system in glucocorticoid-induced monocyte apoptosis. J Immunol 2001; 166:1344–1351.PubMedGoogle Scholar
  255. 255.
    Suda T, Hashimoto H, Tanaka M et al. Membrane Fas ligand kills human peripheral blood T-lymphocytes and soluble Fas ligand blocks the killing. J Exp Med 1997; 186:2045–2050.PubMedCrossRefGoogle Scholar
  256. 256.
    Xiao S, Jodo S, Sung SS et al. A novel signaling mechanism for soluble CD95 ligand. Synergy with anti-CD95 monoclonal antibodies for apoptosis and NF-kappaB nuclear translocation. J Biol Chem 2002; 277:50907–50913.PubMedCrossRefGoogle Scholar
  257. 257.
    Ogasawara J, Watanabe-Fukunaga R, Adachi M et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364:806–809.PubMedCrossRefGoogle Scholar
  258. 258.
    Nishimura Y, Hirabayashi Y, Matsuzaki Y et al. In vivo analysis of Fas antigen-mediated apoptosis: effects of agonistic anti-mouse Fas mAb on thymus, spleen and liver. Int Immunol 1997; 9:307–316.PubMedCrossRefGoogle Scholar
  259. 259.
    Nishimura-Morita Y, Nose M, Inoue T et al. Amelioration of systemic autoimmune disease by the stimulation of apoptosis-promoting receptor Fas with anti-Fas mAb. Int Immunol 1997; 9:1793–1799.PubMedCrossRefGoogle Scholar
  260. 260.
    Ogawa Y, Kuwahara H, Kimura T et al. Therapeutic effect of anti-Fas antibody on a collagen induced arthritis model. J Rheumatol 2001; 28:950–955.PubMedGoogle Scholar
  261. 261.
    Ichikawa K, Yoshida-Kato H, Ohtsuki M et al. A novel murine anti-human Fas mAb which mitigates lymphadenopathy without hepatotoxicity. Int Immunol 2000; 12:555–562.PubMedCrossRefGoogle Scholar
  262. 262.
    Nakayama J, Ogawa Y, Yoshigae Y et al. A humanized anti-human Fas antibody, R-125224, induces apoptosis in type I activated lymphocytes but not in type II cells. Int Immunol 2006; 18:113–124.PubMedCrossRefGoogle Scholar
  263. 263.
    Hiramoto K, Inui M, Kamei T et al. mHFE7A, a newly identified monoclonal antibody to Fas, induces apoptosis in human melanoma cells in vitro and delays the growth of melanoma xenotransplants. Oncol Rep 2006; 15:409–415.PubMedGoogle Scholar
  264. 264.
    Kuwahara H, Tani Y, Ogawa Y et al. Therapeutic effect of novel anti-human Fas antibody HFE7a on graft-versus-host disease model. Clin Immunol 2001; 99:340–346.PubMedCrossRefGoogle Scholar
  265. 265.
    Samel D, Muller D, Gerspach J et al. Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted Activation. J Biol Chem 2003; 278:32077–32082.PubMedCrossRefGoogle Scholar
  266. 266.
    Bremer E, ten Cate B, Samplonius DF et al. Superior activity of fusion protein scfvrit:sfasl over cotreatment with rituximab and Fas agonists. Cancer Res 2008; 68:597–604.PubMedCrossRefGoogle Scholar
  267. 267.
    Bremer E, ten Cate B, Samplonius DF et al. CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia. Blood 2006; 107:2863–2870.PubMedCrossRefGoogle Scholar
  268. 268.
    Scanlan MJ, Raj BK, Calvo B et al. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci USA 1994; 91:5657–5661.PubMedCrossRefGoogle Scholar
  269. 269.
    Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA 1990; 87:7235–7239.PubMedCrossRefGoogle Scholar
  270. 270.
    Assohou-Luty C, Gerspach J, Siegmund D et al. A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95. J Mol Med 2006; 84:785–797.PubMedCrossRefGoogle Scholar
  271. 271.
    Jung G, Grosse-Hovest L, Krammer PH et al. Target cell-restricted triggering of the CD95 (APO-1/Fas) death receptor with bispecific antibody fragments. Cancer Res 2001; 61:1846–1848.PubMedGoogle Scholar
  272. 272.
    Herrmann T, Grosse-Hovest L, Otz T et al. Construction of optimized bispecific antibodies for selective activation of the death receptor CD95. Cancer Res 2008; 68:1221–1227.PubMedCrossRefGoogle Scholar
  273. 273.
    Gerspach J, Muller D, Munkel S et al. Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug. Cell Death Differ 2006; 13:273–284.PubMedCrossRefGoogle Scholar
  274. 274.
    Wajant H, Moosmayer D, Wuest T et al. Differential activation of TRAIL-R1 and-2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 2001; 20:4101–4106.PubMedCrossRefGoogle Scholar
  275. 275.
    Bremer E, Kuijlen J, Samplonius D et al. Target cell-restricted and-enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. Int J Cancer 2004; 20; 109:281–290.PubMedCrossRefGoogle Scholar
  276. 276.
    Bremer E, Samplonius DF, van Genne L et al. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. J Biol Chem 2005; 280:10025–10033.PubMedCrossRefGoogle Scholar
  277. 277.
    Bremer E, Samplonius DF, Peipp M et al. Target cell-restricted apoptosis induction of acute leukemic T-cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7. Cancer Res 2005; 65:3380–3388.PubMedGoogle Scholar
  278. 278.
    Stieglmaier J, Bremer E, Kellner C et al. Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein. Cancer Immunol Immunother 2008; 57:233–246.PubMedCrossRefGoogle Scholar
  279. 279.
    Simon AK, Gallimore A, Jones E et al. Fas ligand breaks tolerance to self-antigens and induces tumor immunity mediated by antibodies. Cancer Cell 2002; 2:315–322.PubMedCrossRefGoogle Scholar
  280. 280.
    Miwa K, Asano M, Horai R et al. Caspase 1-independent IL-1[beta] release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med 1998; 4:1287–1292.PubMedCrossRefGoogle Scholar
  281. 281.
    Behrens CK, Igney FH, Arnold B et al. CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice. J Immunol 2001; 166:3240–3247.PubMedGoogle Scholar
  282. 282.
    Kang SM, Braat D, Schneider DB et al. A noncleavable mutant of Fas ligand does not prevent neutrophilic destruction of islet transplants. Transplantation 2000; 69:1813–1817.PubMedCrossRefGoogle Scholar
  283. 283.
    Allison J, Georgiou HM, Strasser A et al. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA 1997; 94:3943–3947.PubMedCrossRefGoogle Scholar
  284. 284.
    Petrovsky N, Silva D, Socha L et al. The role of Fas ligand in beta cell destruction in autoimmune diabetes of NOD mice. Ann N Y Acad Sci 2002; 958:204–208.PubMedCrossRefGoogle Scholar
  285. 285.
    Silva DG, Petrovsky N, Socha L et al. Mechanisms of accelerated immune-mediated diabetes resulting from islet beta cell expression of a Fas ligand transgene. J Immunol 2003; 170:4996–5002.PubMedGoogle Scholar
  286. 286.
    Lau HT, Yu M, Fontana A et al. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996; 273:109–112.PubMedCrossRefGoogle Scholar
  287. 287.
    Yolcu ES, Askenasy N, Singh NP et al. Cell membrane modification for rapid display of proteins as a novel means of immuno modulation: FasL-decorated cells prevent islet graft rejection. Immunity 2002; 17:795–808.PubMedCrossRefGoogle Scholar
  288. 288.
    Korbutt GS, Elliott JF, Rajotte RV. Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes 1997; 46:317–322.PubMedCrossRefGoogle Scholar
  289. 289.
    Zhang H, Yang Y, Horton JL et al. Amelioration of collagen-induced arthritis by CD95 (Apo-1/ Fas)-ligand gene transfer. J Clin Invest 1997; 100:1951–1957.PubMedCrossRefGoogle Scholar
  290. 290.
    Kim SH, Kim S, Oligino TJ et al. Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL. Mol Ther 2002; 6:584–590.PubMedCrossRefGoogle Scholar
  291. 291.
    Guery L, Batteux F, Bessis N et al. Expression of Fas ligand improves the effect of IL-4 in collagen-induced arthritis. Eur J Immunol 2000; 30:308–315.PubMedCrossRefGoogle Scholar
  292. 292.
    Fleck M, Zhang HG, Kern ER et al. Treatment of chronic sialadenitis in a murine model of Sjogren’s syndrome by local FasL gene transfer. Arthritis Rheum 2001; 44:964–973.PubMedCrossRefGoogle Scholar
  293. 293.
    Morelli AE, Larregina AT, Smith-Arica J et al. Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types and abolish peripheral liver toxicity. J Gen Virol 1999; 80:571–583.PubMedGoogle Scholar
  294. 294.
    Ambar BB, Frei K, Malipiero U et al. Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand. Hum Gene Ther 1999; 10:1641–1648.PubMedCrossRefGoogle Scholar
  295. 295.
    Aoki K, Akyurek LM, San H et al. Restricted expression of an adenoviral vector encoding Fas ligand (CD95L) enhances safety for cancer gene therapy. Mol Ther 2000; 1:555–565.PubMedCrossRefGoogle Scholar
  296. 296.
    Hyer ML, Voelkel-Johnson C, Rubinchik S et al. Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. Mol Ther 2000; 2:348–358.PubMedCrossRefGoogle Scholar
  297. 297.
    Rubinchik S, Ding R, Qiu AJ et al. Adenoviral vector which delivers FasL-GFP fusion protein regulated by the tet-inducible expression system. Gene Ther 2000; 7:875–885.PubMedCrossRefGoogle Scholar
  298. 298.
    Rubinchik S, Wang D, Yu H et al. A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression. Mol Ther 2001; 4:416–426.PubMedCrossRefGoogle Scholar
  299. 299.
    Sipo I, Hurtado PA, Wang X et al. An improved Tet-On regulatable FasL-adenovirus vector system for lung cancer therapy. J Mol Med 2006; 84:215–225.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2009

Authors and Affiliations

  • Martin Ehrenschwender
    • 1
  • Harald Wajant
    • 1
  1. 1.Department of Molecular Internal Medicine, Medical Clinic and Polyclinic IIUniversity of WuerzburgWuerzburgGermany

Personalised recommendations